Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGRXNASDAQ:ELYMNASDAQ:ITRMNASDAQ:QNTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGRXAgile Therapeutics$1.51$1.49$0.20▼$2.63$10.35M1.58352,864 shs120,938 shsELYMEliem Therapeutics$1.26-1.6%$1.25$2.35▼$11.55$152.03M-0.39486,688 shs168,444 shsITRMIterum Therapeutics$0.99-0.9%$1.04$0.81▼$3.02$39.64M2.781.05 million shs459,255 shsQNTMQuantum Biopharma$19.69+3.6%$10.04$2.70▼$21.66$53.29M0.55953,163 shs446,651 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGRXAgile Therapeutics0.00%0.00%0.00%0.00%+320.30%ELYMEliem Therapeutics-1.56%-9.35%+7.69%-6.67%-85.18%ITRMIterum Therapeutics0.00%+2.15%+6.73%-28.20%-17.43%QNTMQuantum Biopharma0.00%+27.44%+115.19%+302.66%+1,968,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGRXAgile Therapeutics0.1207 of 5 stars0.00.00.04.00.00.00.0ELYMEliem TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AITRMIterum Therapeutics2.4201 of 5 stars3.55.00.00.02.70.00.0QNTMQuantum BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGRXAgile Therapeutics 0.00N/AN/AN/AELYMEliem Therapeutics 0.00N/AN/AN/AITRMIterum Therapeutics 3.00Buy$9.00808.27% UpsideQNTMQuantum Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest AGRX, ELYM, QNTM, and ITRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$9.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGRXAgile Therapeutics$19.98M0.52N/AN/A($5.51) per share-0.27ELYMEliem TherapeuticsN/AN/AN/AN/A$3.90 per shareN/AITRMIterum TherapeuticsN/AN/AN/AN/A($0.12) per shareN/AQNTMQuantum BiopharmaN/AN/AN/AN/A$21.29 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGRXAgile Therapeutics-$14.47M-$3.65N/A∞N/A-36.24%N/A-147.37%N/AELYMEliem Therapeutics-$35.12M-$0.53N/A∞N/AN/A-47.03%-45.97%N/AITRMIterum Therapeutics-$24.77M-$0.99N/A∞N/AN/AN/A-90.85%8/13/2025 (Estimated)QNTMQuantum Biopharma-$17.90M-$15.98N/AN/AN/AN/A-84.21%-62.63%8/13/2025 (Estimated)Latest AGRX, ELYM, QNTM, and ITRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025QNTMQuantum Biopharma-$0.37-$1.41-$1.04-$3.53$2.09 million$2.09 million5/13/2025Q1 2025ITRMIterum Therapeutics-$0.14-$0.14N/A-$0.14N/AN/A3/28/2025Q4 2024QNTMQuantum Biopharma-$0.80-$2.89-$2.09-$2.89$0.92 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGRXAgile TherapeuticsN/AN/AN/AN/AN/AELYMEliem TherapeuticsN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/AQNTMQuantum BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGRXAgile TherapeuticsN/A0.560.38ELYMEliem TherapeuticsN/A60.4160.41ITRMIterum TherapeuticsN/A1.411.41QNTMQuantum BiopharmaN/A3.763.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGRXAgile Therapeutics10.92%ELYMEliem Therapeutics69.76%ITRMIterum Therapeutics9.21%QNTMQuantum Biopharma1.24%Insider OwnershipCompanyInsider OwnershipAGRXAgile Therapeutics0.50%ELYMEliem Therapeutics4.70%ITRMIterum Therapeutics9.20%QNTMQuantum Biopharma8.53%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGRXAgile Therapeutics306.86 million6.82 millionNot OptionableELYMEliem Therapeutics929.75 million28.35 millionNot OptionableITRMIterum Therapeutics1040.00 million31.40 millionNot OptionableQNTMQuantum BiopharmaN/A2.71 million1.76 millionN/AAGRX, ELYM, QNTM, and ITRM HeadlinesRecent News About These CompaniesQuantum BioPharma plans special dividend tied to legal actionJune 14 at 9:42 PM | investing.comBest Cannabis Stocks To Add to Your Watchlist - June 13thJune 13 at 2:15 PM | marketbeat.comQuantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement ProceedsJune 13 at 7:00 AM | globenewswire.comQuantum BioPharma Boosts Digital Asset Holdings to $5 Million with New Bitcoin PurchaseJune 10, 2025 | bitcoinmagazine.comQuantum Biopharma (NASDAQ:QNTM) Stock Rating Upgraded by Wall Street ZenJune 8, 2025 | americanbankingnews.comQuantum BioPharma clarifies misinformation on stock name, RTO rumorsJune 4, 2025 | investing.comQuantum BioPharma Clarifies Name Confusion, Refutes RTO Rumors With Unbuzzd WellnessJune 4, 2025 | nasdaq.comQuantum BioPharma Clarifies It Has Not Changed Its NameJune 3, 2025 | globenewswire.comiNGENū CRO Partners with Quantum BioPharma to Launch Pioneering Australian Clinical Trial for Chronic Nociplastic Pain in MCAS PatientsJune 2, 2025 | globenewswire.comQuantum BioPharma settles disputes with former CEOJune 1, 2025 | uk.investing.comWhat's Going On With Quantum Biopharma Stock Today?May 30, 2025 | benzinga.comQuantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza BokhariMay 30, 2025 | globenewswire.comQuantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc.May 29, 2025 | globenewswire.comQuantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation SyndromeMay 28, 2025 | globenewswire.comQuantum BioPharma Increases Crypto Holdings To $4.5 Mln For Strategic GrowthMay 21, 2025 | nasdaq.comQuantum BioPharma Partners with BitGo to Securely Store its Crypto Currency AssetsMay 21, 2025 | thestar.comQuantum Biopharma Announces Signing of an Agreement with a Global Pharmaceutical Contract Research Organization to Prepare an IND (Investigational New Drug) Application Package for Lucid-21-302 (Lucid-MS), A First-In-Class Treatment for Multiple SclerosisMay 20, 2025 | globenewswire.comQuantum Biopharma Purchases an Additional USD $1 Million of Bitcoin and Other Cryptocurrencies to Hold BTC Treasury and To Generate Staking Revenue. Bringing the Total Investment in Digital Assets to USD $4,500,000May 19, 2025 | globenewswire.comQuantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare ConferenceMay 16, 2025 | globenewswire.comQuantum BioPharma Completes Dosing in 90-Day Toxicity Studies for Multiple Sclerosis Drug Lucid-21-302, Advancing Toward IND SubmissionMay 13, 2025 | nasdaq.comQuantum Biopharma to seek FDA OK for Phase 2 trial of Lucid-MSMay 13, 2025 | multiplesclerosisnewstoday.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAGRX, ELYM, QNTM, and ITRM Company DescriptionsAgile Therapeutics NASDAQ:AGRXAgile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.Eliem Therapeutics NASDAQ:ELYM$1.26 -0.02 (-1.56%) As of 06/13/2025Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.Iterum Therapeutics NASDAQ:ITRM$0.99 -0.01 (-0.91%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.00 +0.01 (+0.92%) As of 06/13/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Quantum Biopharma NASDAQ:QNTM$19.69 +0.69 (+3.63%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$19.88 +0.18 (+0.94%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
